8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 5, 2014)

Filed November 5, 2014For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on November 5, 2014, to report its financial results for the third quarter ended September 30, 2014. The report primarily consists of a press release detailing these financial and operational updates. Investors can find key performance indicators and strategic developments within the furnished press release (Exhibit 99.1), which serves as the core of this filing. This 8-K provides a snapshot of the company's performance and financial condition during the specified quarter. While the 8-K itself is brief, it signals the company's commitment to timely disclosure of financial performance. Investors should refer to the attached press release for detailed financial metrics, including revenue, expenses, and net income/loss, as well as any management commentary on the results and outlook. The filing indicates that Alnylam is adhering to its reporting obligations, offering stakeholders insight into its ongoing operations and financial standing as of Q3 2014.

Key Highlights

  • 1Alnylam Pharmaceuticals reported its financial results for the third quarter ended September 30, 2014, via an 8-K filing on November 5, 2014.
  • 2The primary content of the filing is a press release (Exhibit 99.1) containing the detailed financial and operational results.
  • 3This filing serves as Alnylam's official communication of its Q3 2014 performance to the investing public.
  • 4The information provided is not deemed 'filed' for Section 18 purposes, but is furnished for investor information.
  • 5Investors should consult the referenced press release for specific financial figures and management's discussion.
  • 6The 8-K confirms Alnylam's adherence to its SEC reporting schedule.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Alnylam Pharmaceuticals' financial results for the third quarter ended September 30, 2014. It includes a press release that contains the detailed financial and operational performance for that period.

The specific financial details for the third quarter ended September 30, 2014, are located in the press release furnished as Exhibit 99.1 to this 8-K filing. This press release is the primary source for numerical data and management commentary.

No, the information in this 8-K filing, specifically the press release (Exhibit 99.1), is furnished and not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, unless expressly incorporated by reference into a future SEC filing.

This section indicates that Alnylam Pharmaceuticals announced its quarterly financial results on November 5, 2014, and that these results are being reported via a press release, which is attached as an exhibit to the 8-K.